Article
Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $27
Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $26 to $27.
Comments
- No comments yet. Be the first to comment!